Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Gregory G., Szarek, Michael, Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Landmesser, Ulf, López-Jaramillo, Patricio, Manvelian, Garen, Pordy, Robert, Scemama, Michel, Sinnaeve, Peter R., White, Harvey D., Steg, Ph Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822604/
https://www.ncbi.nlm.nih.gov/pubmed/34325831
http://dx.doi.org/10.1016/j.jacc.2021.04.102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822604/
https://www.ncbi.nlm.nih.gov/pubmed/34325831
http://dx.doi.org/10.1016/j.jacc.2021.04.102

Ejemplares similares